Biomarkers Associated with Response to Vedolizumab

Vedolizumab is an anti-α4β7 monoclonal antibody approved for the treatment of inflammatory bowel disease (IBD).  A recent study finds that pretreatment α4β7 expression and α4β7 receptor saturation during maintenance therapy were identified as candidate biomarkers for vedolizumab response. This assay leads to promise that we will be able to identify good candidates for biologic therapies